Novo Nordisk A/S Competitors

Johnson & Johnson (NYSE:JNJ) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Johnson & Johnson and Novo Nordisk A/S, as provided by MarketBeat.com.

Johnson & Johnson presently has a consensus target price of $180.6429, indicating a potential upside of 11.98%. Novo Nordisk A/S has a consensus target price of $72.00, indicating a potential upside of 3.31%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, research analysts clearly believe Johnson & Johnson is more favorable than Novo Nordisk A/S.

Volatility and Risk

Johnson & Johnson has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Insider & Institutional Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. Comparatively, 5.9% of Novo Nordisk A/S shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Novo Nordisk A/S has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Johnson & Johnson and Novo Nordisk A/S's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Johnson & Johnson and Novo Nordisk A/S's gross revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Novo Nordisk A/S. Johnson & Johnson is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Johnson & Johnson beats Novo Nordisk A/S on 12 of the 17 factors compared between the two stocks.

Novo Nordisk A/S (NYSE:NVO) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Profitability

This table compares Novo Nordisk A/S and Abbott Laboratories' net margins, return on equity and return on assets.

Insider and Institutional Ownership

5.9% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S has raised its dividend for 1 consecutive years and Abbott Laboratories has raised its dividend for 49 consecutive years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Novo Nordisk A/S and Abbott Laboratories, as provided by MarketBeat.com.

Novo Nordisk A/S currently has a consensus price target of $72.00, suggesting a potential upside of 3.31%. Abbott Laboratories has a consensus price target of $122.0556, suggesting a potential upside of 0.96%. Given Novo Nordisk A/S's higher possible upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Abbott Laboratories.

Valuation & Earnings

This table compares Novo Nordisk A/S and Abbott Laboratories' top-line revenue, earnings per share and valuation.

Novo Nordisk A/S has higher earnings, but lower revenue than Abbott Laboratories. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Novo Nordisk A/S has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Novo Nordisk A/S on 9 of the 17 factors compared between the two stocks.

Novo Nordisk A/S (NYSE:NVO) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares Novo Nordisk A/S and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Novo Nordisk A/S. Pfizer is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Novo Nordisk A/S has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Dividends

Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.3%. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Pfizer pays out 52.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S has increased its dividend for 1 consecutive years and Pfizer has increased its dividend for 1 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

Insider and Institutional Ownership

5.9% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Novo Nordisk A/S and Pfizer's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for Novo Nordisk A/S and Pfizer, as provided by MarketBeat.com.

Novo Nordisk A/S currently has a consensus price target of $72.00, indicating a potential upside of 3.31%. Pfizer has a consensus price target of $38.5714, indicating a potential upside of 5.59%. Given Pfizer's stronger consensus rating and higher probable upside, analysts plainly believe Pfizer is more favorable than Novo Nordisk A/S.

Summary

Pfizer beats Novo Nordisk A/S on 10 of the 15 factors compared between the two stocks.

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Novartis and Novo Nordisk A/S's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Novartis and Novo Nordisk A/S, as provided by MarketBeat.

Novartis currently has a consensus target price of $108.50, suggesting a potential upside of 23.97%. Novo Nordisk A/S has a consensus target price of $72.00, suggesting a potential upside of 3.31%. Given Novartis' stronger consensus rating and higher possible upside, analysts clearly believe Novartis is more favorable than Novo Nordisk A/S.

Earnings & Valuation

This table compares Novartis and Novo Nordisk A/S's revenue, earnings per share and valuation.

Novartis has higher revenue and earnings than Novo Nordisk A/S. Novartis is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Novartis has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Insider & Institutional Ownership

9.9% of Novartis shares are owned by institutional investors. Comparatively, 5.9% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.4%. Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. Novartis pays out 39.7% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has increased its dividend for 1 consecutive years and Novo Nordisk A/S has increased its dividend for 1 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Novartis beats Novo Nordisk A/S on 11 of the 16 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Risk and Volatility

Merck & Co., Inc. has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Earnings & Valuation

This table compares Merck & Co., Inc. and Novo Nordisk A/S's gross revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Novo Nordisk A/S. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 5.9% of Novo Nordisk A/S shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Merck & Co., Inc. and Novo Nordisk A/S, as reported by MarketBeat.com.

Merck & Co., Inc. currently has a consensus price target of $95.9167, suggesting a potential upside of 25.74%. Novo Nordisk A/S has a consensus price target of $72.00, suggesting a potential upside of 3.31%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, equities analysts plainly believe Merck & Co., Inc. is more favorable than Novo Nordisk A/S.

Profitability

This table compares Merck & Co., Inc. and Novo Nordisk A/S's net margins, return on equity and return on assets.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Novo Nordisk A/S has increased its dividend for 1 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Merck & Co., Inc. beats Novo Nordisk A/S on 10 of the 16 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Profitability

This table compares AbbVie and Novo Nordisk A/S's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for AbbVie and Novo Nordisk A/S, as reported by MarketBeat.

AbbVie currently has a consensus target price of $115.75, indicating a potential upside of 7.21%. Novo Nordisk A/S has a consensus target price of $72.00, indicating a potential upside of 3.31%. Given AbbVie's stronger consensus rating and higher possible upside, equities research analysts clearly believe AbbVie is more favorable than Novo Nordisk A/S.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.8%. Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.9%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 54.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Novo Nordisk A/S has increased its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility & Risk

AbbVie has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Institutional and Insider Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 5.9% of Novo Nordisk A/S shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares AbbVie and Novo Nordisk A/S's gross revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Novo Nordisk A/S. AbbVie is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Novo Nordisk A/S on 12 of the 17 factors compared between the two stocks.